Libtayo® (cemiplimab) is now approved in Canada for the treatment of BCC

Tagged: 

Viewing 0 reply threads
  • Author
    Posts
    • #42400
      Mary Zawadzki
      Keymaster

      Incredible news for Canadian patients suffering from the most common form of skin cancer, and the most frequently occurring cancer of all cancers worldwide, Basal Cell Carcinoma.
      Libtayo® (cemiplimab) is now approved in Canada for the treatment of adults with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI).Thank you to everyone who participated in our patient survey submission to help make this possible! Read more here

Viewing 0 reply threads
  • You must be logged in to reply to this topic.
Menu